| TEST CHANGE |  |
| :---: | :---: |
| Drugs of Abuse Confirmation/Qualitative - Cannabinoids (Marijuana_Metabolite, ) Meconium, Qualitative |  |
| Specimen Requirements: |  |
| Patient Preparation: |  |
| Collect: | All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears. |
| Specimen Preparation: | Transport 0.5 g (equivalent to $1 / 2$ inch cube) for each separate confirmation required. (Min: 0.13 g or $1 / 4$ inch cube) |
| Transport Temperature: | Room temperature. |
| Unacceptable Conditions: |  |
| Remarks: |  |
| Stability: | Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year |
| Methodology: | Liquid Chromatography-Tandem Mass Spectrometry |
| Performed: | Sun-Sat |
| Reported: | 1-4 days |

Note:
CPT Codes: 80349 (Alt code: G0480)

New York DOH Approval Status: This test is New York DOH approved.

```
Interpretive Data:
```

Drugs Covered: 9-carboxy-THC
Positive cutoff: $5 \mathrm{ng} / \mathrm{g}$

Meconium begins to form between the 12th and 16 th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S.US Food and Drug Administration. This test was performed in a CLIA _certified laboratory and is intended for clinical purposes.

Reference Interval:

